Placebo not non-inferior to colchicine in preventing gout flares in the first 6 months of starting allopurinol using ’start-low go-slow’ strategy. Introduction Gout is a very common condition, affecting up to 4% of adults in developed countries. The symptoms tend to flare every so often, developing over a few hours and causing severe pain in […]
Category: Gout
Flare likely after vaccination, but can be prevented with colchicine
COVID-19 vaccination associated with increased likelihood of gout flare INTRODUCTIONM Gout is a very common condition, affecting up to 2–4% of adults in developed countries. The symptoms tend to flare every so often, developing over a few hours and causing severe pain in the joints. It is caused by deposits of crystals of a substance […]
Fully vaccinated people with systemic rheumatic diseases have less severe COVID outcomes
Breakthrough COVID-19 had lower hospitalisation and mortality in vaccinated patients INTRODUCTION COVID-19 is the disease caused by a new type of coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It was declared a pandemic by the World Health Organization on 11 March 2020. COVID-19 has forced people to change their behaviours to try to limit […]
Cardiovascular risk management in rheumatic diseases
This is the lay version of the EULAR recommendations for managing cardiovascular risks in people with rheumatic and musculoskeletal diseases. The original publication can be downloaded from the EULAR website: www.eular.org. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and […]
Reduce body fat to minimise risk of developing gout
Excess adiposity and genetic predisposition are strongly associated with a higher risk of gout, particularly in women. INTRODUCTION Gout is a very common condition, affecting up to 2–4% of adults in developed countries. The symptoms tend to flare every so often, developing over a few hours and causing severe pain in the joints. It is […]
Gout flare in people in hospital can be predicted
Hospitalisation increases the risk of gout flare, but risks can be assessed and steps taken to prevent it. Introduction Gout is one of the most common inflammatory conditions, affecting up to 2% of adults in developed countries. It is caused by long-standing deposits of crystals of a substance called uric acid (urate) in the joints. […]
Managing gout
This is the lay version of the EULAR recommendations for the management of people with gout. The original publication can be downloaded from the EULAR website: www.eular.org. Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29–42. doi:10.1136/annrheumdis-2016-209707 Introduction EULAR recommendations give advice to doctors, nurses and […]
Risk of side effects increased in people from certain racial or ethnic backgrounds
Allopurinol should be used with caution in people with Black, Asian, or Native Hawaiian/Pacific Islander heritage. Introduction Gout is a very common condition. It is caused by deposits of crystals of a substance called uric acid (also known as urate) in the joints, which leads to inflammation. Periods of time when you have gout symptoms […]
The CLEAR-2 study suggests a role for two combined medicines to treat gout
Lesinurad in combination with allopurinol lowers uric acid levels better than allopurinol alone in people with gout INTRODUCTION Gout is a very common condition. It is caused by deposits of crystals of a substance called uric acid (also known as urate) in the joints, which leads to inflammation. Periods of time when you have gout […]
Treat-to-target could be a reality in gout
Targeting urate levels could help to improve care for people with gout. INTRODUCTION Gout is a very common condition, affecting up to 2% of adults in developed countries. The symptoms tend to flare every so often, developing over a few hours and causing severe pain in the joints. It is caused by deposits of crystals […]
